Vectibix Side Effects
Generic Name: panitumumab
Note: This document contains side effect information about panitumumab. Some of the dosage forms listed on this page may not apply to the brand name Vectibix.
Some side effects of Vectibix may not be reported. Always consult your doctor or healthcare specialist for medical advice. You may also report side effects to the FDA.
For the Consumer
Applies to panitumumab: intravenous solution
Along with its needed effects, panitumumab (the active ingredient contained in Vectibix) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking panitumumab:More common
- Abdominal or stomach pain
- bloating or swelling of the face, arms, hands, lower legs, ankles, or feet
- chest pain
- decreased urination
- deep cracks, grooves, or lines in the skin
- difficulty with swallowing
- discoloration of the fingernails or toenails
- dry mouth, lips, or skin
- fast or irregular heartbeat
- flushing or redness of the skin
- increased thirst
- itching, pain, and swelling of the eyelid
- itching skin
- loosening of the fingernails
- loss of appetite
- mood or mental changes
- muscle pain or cramps
- muscle spasms or twitching
- rapid weight gain
- rapid, shallow breathing
- redness or soreness around the fingernails
- shortness of breath
- sores, ulcers, or white spots on the lips, tongue, or inside the mouth
- sudden shortness of breath
- sunken eyes
- swelling or inflammation of the mouth
- tearing of the eyes
- tingling of the hands or feet
- troubled breathing
- unusual tiredness or weakness
- unusual weight gain or loss
- unusually warm skin
- Blurred vision
- burning, dry, or itching eyes
- difficulty with breathing
- discharge from the eyes or excessive tearing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- facial swelling
- noisy breathing
- puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue
- swelling of the eye, eyelid, or inner lining of the eyelid
- tightness in the chest
- Chest discomfort
- painful breathing
- slight fever
- troubled or quick, shallow breathing
- Bleeding, blistering, burning, coldness, discoloration of the skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, or warmth at the injection site
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs
For Healthcare Professionals
Applies to panitumumab: intravenous solution
Dermatologic side effects including all skin/integument toxicity (90%), erythema (65%), acneiform dermatitis (57%), pruritus (57%), skin exfoliation (25%), paronychia (25%), rash (22%), skin fissures (20%), acne (13%), dry skin (10%), nail disorders (9%), and growth of eyelashes (6%) have been reported.
Dermatologic toxicities related to the panitumumab (the active ingredient contained in Vectibix) blockade of EGF binding and subsequent inhibition of EGFR-mediated signaling were severe in 16% of patients with metastatic colorectal cancer receiving panitumumab. Subsequent to the development of severe dermatologic toxicities infectious complications including sepsis, septic death, and abscesses requiring incisions and drainage were reported.
Animal studies have reported dermatologic findings, including dermatitis, pustule formation, exfoliative rash, and deaths secondary to bacterial infection and sepsis.
General side effects including fatigue (26%) and general deterioration (11%) have been reported.
When used in combination with irinotecan, the incidence and severity of diarrhea is increased. In a study of 19 patients who received panitumumab (the active ingredient contained in Vectibix) in combination with irinotecan, 5-fluorouracil, and leucovorin, the incidence of grade 3 or 4 diarrhea was 58% and was fatal in one patient. The combination of panitumumab with leucovorin is not recommended.
Gastrointestinal side effects including abdominal pain (25%), nausea (23%), diarrhea (21%), constipation (21%), vomiting (19%), stomatitis (7%), and mucosal inflammation (6%) have been reported.
Metabolic side effects including hypomagnesemia (39%) and peripheral edema (12%) have been reported.
Median magnesium levels decreased by 0.1 mmol/L. Hypomagnesemia (grade 3 or 4) requiring oral or IV electrolyte repletion occurred in 2% of patients. Hypomagnesemia occurred 6 weeks or longer after the initiation of panitumumab. In some patients, hypomagnesemia was associated with hypocalcemia. Patient's electrolytes should be monitored during and for eight weeks after the completion of panitumumab therapy. Patients should be periodically monitored for hypomagnesemia and accompanying hypocalcemia during the eight weeks after the completion of panitumumab therapy.
Panitumumab (the active ingredient contained in Vectibix) should be permanently discontinued in patients developing interstitial lung disease, pneumonitis, or lung infiltrates.
Respiratory side effects including cough (14%), pulmonary embolism, and pulmonary fibrosis (reported in less than 1%) have been reported.
Ocular side effects (15%) have been reported.
Hypersensitivity side effects have been reported. Four percent of patients have experienced an infusion reaction and 1% of those were severe.
Severe infusion reactions were identified as anaphylactic reaction, bronchospasm, fever, chills, and hypotension. Although fatal infusion reactions have not been reported with panitumumab, fatalities have occurred with other monoclonal antibody products. The infusion should be stopped if a severe infusion reaction occurs. Depending on the severity and/or persistence of the reaction, panitumumab may need to be permanently discontinued.
Cardiovascular side effects including angioedema have been reported.
More about Vectibix (panitumumab)
Compare with other treatments for:
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.